Key facts
- It has raised $25.9M across 5 recorded rounds; the latest was Seed Round ($2.5M) in Sep 2025.
- Notable investors include 5Y Capital, BOPU Capital, Checkmate Capital, Hike Capital, IMO Ventures — 7 tracked in total.
- Hopewell Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently Sep 2025 ($2.5M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Hopewell Therapeutics
Funding rounds
5 roundsAbout Hopewell Therapeutics
Developer of novel biodegradable lipid nanoparticles designed to give technology and services to bring genomic medicines to patients. The company's technology is developed through novel synthetic lipid-based nanoparticles for nucleic acid delivery for gene therapy and gene editing, enabling healthcare professionals to understand immunotherapy, gene therapy, and gene editing.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2018
- Employees
- 19
- Website
- hopewell-tx.com/
- Ownership
- Privately Held (backing)
Hopewell Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hopewell Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hopewell Therapeutics in its N-PORT filings yet. We sweep new filings monthly.